Abstract

Recent evidence suggests that blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab may benefit patients undergoing percutaneous

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call